Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Cash from Financing Activities data on file, last reported at $394.2 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 13285.13% year-over-year to $394.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $478.0 million (up 19.8% YoY) and the FY2025 annual result came in at $478.0 million, up 19.8% from the prior year.
• Cash from Financing Activities climbed to $394.2 million in Q4 2025 per RARE's latest filing, from $2000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $491.9 million in Q3 2022 and bottomed at -$722000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $11.9 million (2021), against an average of $94.2 million.
• Peak annual rise in Cash from Financing Activities reached 17459.4% in 2023, while the deepest fall reached 144.79% in 2023.
• Tracing RARE's Cash from Financing Activities over 5 years: stood at $85.7 million in 2021, then plunged by 97.8% to $1.9 million in 2022, then surged by 17459.4% to $330.5 million in 2023, then slumped by 99.11% to $2.9 million in 2024, then surged by 13285.13% to $394.2 million in 2025.
• Per Business Quant, the three latest RARE Cash from Financing Activities figures stand at $394.2 million (Q4 2025), $2000.0 (Q3 2025), and $83.6 million (Q2 2025).

Peer Comparison